Press Releases

 
Press Releases
  Date Title View
Jun 1, 2016
LEXINGTON, MA -- (Marketwired) -- 06/01/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced the closing of its previously announced underwritten public offering. Aldeyra sold 2,760,000 shares of its common stock, includi...
PDF
May 26, 2016
LEXINGTON, MA -- (Marketwired) -- 05/26/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced the pricing of an underwritten public offering of 2,400,000 shares of its common stock at a price to the public of $5.00 per sha...
PDF
May 25, 2016
LEXINGTON, MA -- (Marketwired) -- 05/25/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to mark...
PDF
May 9, 2016
LEXINGTON, MA -- (Marketwired) -- 05/09/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today reported that a randomized, multi-center, investigator-masked, comparator-controlled, parallel-group Phase II clinical trial of topical ocu...
PDF
May 5, 2016
LEXINGTON, MA -- (Marketwired) -- 05/05/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will issue its financial results for the first quarter ended March 31, 2016 on Monday, May 9, 2016, prior to the market ...
PDF
Mar 30, 2016
LEXINGTON, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced its financial results for the year ended December 31, 2015. "We are pleased with the progres...
PDF
Mar 30, 2016
LEXINGTON, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced its financial results for the year ended December 31, 2015. "We are pleased with the progression of our clinical develo...
PDF
Mar 24, 2016
LEXINGTON, Mass., March 24, 2016 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that David J. Clark, M.D., Chief Medical Officer of Aldeyra, will present at the 2016 SSADH Symposium on M...
PDF
Mar 16, 2016
LEXINGTON, Mass., March 16, 2016 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2015 on Wed...
PDF
Mar 3, 2016
LEXINGTON, Mass., March 03, 2016 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the Cowen and Company 36th ...
PDF
Page: FirstPrevious
3
... NextLast